Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
GENFIT AND LABCORP SIGN A LICENSING AGREEMENT TO EXPAND ACCESS TO AN INNOVATIVE DIAGNOSTIC ASSAY FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, FRANCE; CAMBRIDGE, MASS.; AND BURLINGTON, N.C.—January 3,2019
Voorlopige financiële kalender voor 2019: 4 februari 2019: publicatie van de jaarresultaten van 2018; de jaarrekening en het financieel verslag worden voor het einde van april 2019 openbaar gemaakt. 30 april 2019: publicatie van de omzet en kaspositie per 31 maart 2019. 13 juni 2019: jaarlijkse algemene vergadering, in Lille. 30 september 2019: publicatie van halfjaarresultaten 2019. 30 oktober 2019: publicatie van de verkoop en kaspositie op 30 september 2019.
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018 GENFIT achieved significant development milestones in 2018: * Completed enrollment of interim analysis cohort for phase 3 RESOLVE-IT trial in NASH * Announced positive results in phase 2 trial of elafibranor in PBC * Entered into licensing agreement with LabCorp®for NASH diagnostic * Launched a U.S. phase 2 investigator-initiated trial of nitazoxanide in patients with NASH-induced fibrosis Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Genfit SA (OTCPK:GNFTF) initiated with Buy rating and a €46 (144% upside) price target at B. Riley FBR citing an expected positive outcome from the Phase 3 RESOLVE-IT study evaluating elafibranor in NASH.
"French drugmaker Genfit (NASDAQOTH: GNFTF) expects to report interim results from a phase 3 study of elafibranor in treating NASH later in 2019. The company could be set to file for regulatory approval in the NASH indication by late 2020 or early 2021. Elafibranor could potentially be viewed as more effective and safer than Ocaliva based on earlier clinical results. Genfit is also evaluating elafibranor in treating PBC, with positive phase 2 results announced in December 2018."finance.yahoo.com/news/intercept-phar...
bijzondere koersreactie op PB van Intercept inzake Fibrosis/NASH Genfit eerste reaktie minus 3%, daarna bedacht men dat het eigenlijk ook goed nieuws voor Genfit kan zijn, en zie daar Genfit +7%
nelis h schreef op 19 februari 2019 14:57 :
bijzondere koersreactie op PB van Intercept inzake Fibrosis/NASH
Genfit eerste reaktie minus 3%, daarna bedacht men dat het eigenlijk ook goed nieuws voor Genfit kan zijn, en zie daar Genfit +7%
Waarschijnlijk omdat die resultaten van Intercept niet echt bijzonder zijn. "The study showed that a higher number of patients in the two dosage arms achieved the main goal of NASH resolution with no worsening of liver fibrosis compared with a placebo, but the company said it was not statistically significant . Analysts said the main goal of fibrosis improvement was likely more important for an approval as well as potential use."
Dr. Bob schreef op 19 februari 2019 16:43 :
[...]
Waarschijnlijk omdat die resultaten van Intercept niet echt bijzonder zijn.
"The study showed that a higher number of patients in the two dosage arms achieved the main goal of NASH resolution with no worsening of liver fibrosis compared with a placebo, but the company said it was not statistically significant . Analysts said the main goal of fibrosis improvement was likely more important for an approval as well as potential use." Hetzelfde geldt voor Genfit.
DeZwarteRidder schreef op 19 februari 2019 16:47 :
[...]
Hetzelfde geldt voor Genfit.
De resultaten van Genfit worden eerst eind 2019 verwacht. U verbaast ons met uw helderziende gaven. Is er wellicht meer dat u met ons wilt delen?
en we stijgen ridderlijk nog even door
nelis h schreef op 20 februari 2019 12:23 :
en we stijgen ridderlijk nog even door
De stijging berust op een vergissing, dus dat komt heus wel weer in orde...
Bij Intercept hebben ze inmiddels ontdekt dat de stijging naar ca 125 USD op een grote vergissing berust. De koers staat nu op ca 92 USD.
GENFIT : FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING IN THE UNITED STATESglobenewswire.com/news-release/2019/0...
dat zal ook wel op een vergissing berusten :) wel een fijne koersreactie
Brouya schreef op 28 februari 2019 07:43 :
GENFIT : FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING IN THE UNITED STATES
globenewswire.com/news-release/2019/0... Anders gezegd: niemand wil deze tent overnemen of er mee samenwerken. En het geld is op. Dat zegt al genoeg......!!!
DeZwarteRidder schreef op 28 februari 2019 09:34 :
[...]
Anders gezegd: niemand wil deze tent overnemen of er mee samenwerken.
En het geld is op.
Dat zegt al genoeg......!!!
Je hebt helemaal gelijk. GALAPAGOS EN ARGENX gingen voor;)
Brouya schreef op 28 februari 2019 09:57 :
[...]Je hebt helemaal gelijk.
GALAPAGOS EN ARGENX gingen voor;)
Je wordt niet rijk door het vergelijken van appels en peren.
Dr. Bob schreef op 1 maart 2019 12:54 :
Genfit files for a $100 million US IPO www.nasdaq.com/article/nash-biotech-g... NASH biotech Genfit files for a $100 million US IPO February 27, 2019, 04:21:00 PM EDT By Renaissance Capital, Renaissance Capital Genfit, a Phase 3 biotech developing therapies for NASH, filed on Wednesday with the SEC to raise up to $100 million in a US initial public offering. The Loos, France-based company was founded in 1999 and booked $9 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol GNFT. Genfit filed confidentially on November 16, 2018. SVB Leerink and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed. The article NASH biotech Genfit files for a $100 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Onderstaand de events die Genfit de komende maanden zal bijwonen. March 12-14, 2019, Barclays Global Healthcare Conference, Miami, US March 17-19, 2019, Annual ROTH Conference, Orange County, US March 28, 2019, ROTH Battle of the NASH Thrones Spring Conference, New York, US April 4-5, 2019, CM-CIC Market Solutions Forum by ESN, Paris, France April 7-9, 2019, LHC Wainwright & Co. Global Life Sciences Conference, London, UK April 9-10, 2019, Portzamparc MidCap Conference, Paris, France April 11-14, 2019, 2019 International Liver Congress™, Vienna, Austria April 16-17, 2019 Kempen Life Sciences Conference, Amsterdam, The Netherlands April 16-17, 2019, SmallCap Event, Paris, France April 22-25, 2019, 3rd Annual NASH Summit, Boston, US April 26-27, 2019 - 1st International Workshop of the SHIVER Network, Montreal Canada June 7 - 11, 2019 - US79th Scientific Sessions of the ADA, San Francisco, US July 11 - 12, 2019 - NASH Meeting 2019, Paris, France
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee